Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Feasibility and Acceptability of Remote Saliva Collection

2 november 2026 bijgewerkt door: St. Jude Children's Research Hospital

The purpose of this study is to evaluate the practicality and acceptability of collecting biological samples and health information from childhood survivors of acute lymphoblastic leukemia (ALL) and their siblings. Participants will provide saliva, blood, hair, and fingernail samples, complete questionnaires, and participate in sleep monitoring. The information collected will help researchers understand how cancer treatment and neighborhood conditions may affect stress hormones, inflammation, and long-term health.

Primary Objective

- To evaluate the feasibility of collecting multiple biological specimens, surveys, and sleep assessment among child and adolescent survivors of ALL and their siblings.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Childhood survivors of acute lymphoblastic leukemia (ALL) can experience long-term health problems after cancer treatment. Researchers believe that stress-related biological processes and social factors, such as neighborhood socioeconomic conditions, may influence long-term health outcomes. However, it is not known whether collecting multiple biological samples over several days is practical for survivors and their families.

This feasibility and acceptability study will enroll survivors of childhood ALL, their siblings, and caregivers. Participants may complete study activities through a combination of in-person and remote procedures or through a fully remote option.

Participants will complete an enrollment visit, a baseline visit conducted either in person or remotely, and a telehealth reminder visit. Survivors and siblings will provide saliva, blood, hair, and fingernail samples. Saliva samples will be collected at home five times per day over three days. Participants will also wear a WatchPAT sleep monitoring device and complete morning and evening diaries during the saliva collection period. Questionnaires will assess demographic information, sleep, emotional well-being, family relationships, health behaviors, and other factors that may influence cortisol measurements. Caregivers will complete questionnaires about household and demographic characteristics and provide feedback regarding study acceptability.

Blood samples will be used to measure markers of inflammation and hormone function. Saliva, hair, and fingernail samples will be used to evaluate cortisol, a biological marker related to stress and hypothalamic-pituitary-adrenal (HPA) axis functioning. The study will also explore associations between neighborhood socioeconomic status and biological measures of cortisol and inflammation. Findings from this feasibility study will be used to inform the design of future research investigating the effects of cancer treatment and social environments on long-term health outcomes among childhood ALL survivors.

Studietype

Observationeel

Inschrijving (Geschat)

100

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Verenigde Staten
    • Tennessee
      • Memphis, Tennessee, Verenigde Staten, 38105
        • Werving
        • St. Jude Children's Research Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Bria Gresham, PhD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

8 jaar tot 18 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population will include child and adolescent survivors of ALL, their siblings, and caregivers.

Beschrijving

Inclusion Criteria:

SURVIVORS

  • The survivor is a childhood survivor of Acute Lymphocytic Leukemia (ALL).

  • The survivor was treated on one of the following St. Jude Total Therapy Studies:

    1. TOTAL Therapy study XVI for Newly Diagnosed Patients with ALL (TOTXVI) OR
    2. Total Therapy for Children with Acute Lymphoblastic Leukemia and Lymphoma (TOT17)

  • The survivor is cancer-free.

  • The survivor is at least 5 years out from the ALL diagnosis.

  • The survivor is at least 2 years out from completion of treatment.

  • The survivor did not receive cranial therapy as part of ALL therapy.

  • The survivor is aged ≥8 to 18 years old at the time of enrollment.

  • The survivor has completed their After Completion of Therapy (ACT) clinic consultation.

  • The survivor is able to speak and read English.

  • The survivor has internet access.

SIBLINGS

  • The sibling has a brother or sister who is an ALL survivor participating in this study.
  • The sibling is aged ≥8 to18 years old at the time of enrollment.
  • The sibling is able to speak and read English.
  • The sibling has internet access.

CAREGIVERS

  • The caregiver provides primary care or support to an ALL survivor that is in this study.
  • The caregiver resides in the home full-time with enrolled survivor and sibling.
  • The caregiver is able to speak and read English.
  • The caregiver has internet access.
  • The caregiver is willing and able to assist with at home biospecimen collection.

Exclusion Criteria:

SURVIVORS and SIBLINGS

  • Survivor and/or sibling has a diagnosis of Down's Syndrome.
  • Survivor and/or sibling has a diagnosis of autism spectrum disorder.
  • Survivor and/or sibling has a diagnosis of another pervasive developmental disorder not listed above.
  • Survivor and/or sibling has a history of prolonged treatment with steroid medications or systemic glucocorticoids for reasons other than ALL.
  • Survivor and/or sibling resides outside of the United States.
  • Inability or unwillingness of survivor and/or sibling and/or legal guardian/representative to give written informed consent.

CAREGIVERS Note: There are no exclusion criteria for caregivers.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Childhood ALL Survivors

Childhood survivors of acute lymphoblastic leukemia treated on St. Jude Total Therapy XVI or Total Therapy 17 protocols who meet survivorship and age eligibility requirements.
Diagnostische toets: Salivary Cortisol Collection

Participants collect five saliva samples per day on three days within a 14-day period (wake, +30 min, +45 min, +60 min, bedtime) to assess diurnal cortisol rhythm and cortisol awakening response.

Andere namen:
  • Saliva Sampling; Saliva Collection
Diagnostische toets: Blood Biomarker Collection

Collection of blood samples to measure high-sensitivity C-reactive protein, pro-inflammatory cytokines, dehydroepiandrosterone, and luteinizing hormone. Hybrid participants undergo venipuncture (~3 mL blood). Remote participants use the FDA-approved RedDrop One capillary blood collection device.

Andere namen:
  • Blood Collection; Blood Sampling; Venipuncture; RedDrop One Blood Collection
Diagnostische toets: Hair Cortisol Collection

Collection of a small hair sample from the posterior vertex of the scalp to measure long-term cortisol exposure. Hair is cut close to the scalp and stored for laboratory analysis.

Andere namen:
  • Hair Sample Collection
Diagnostische toets: Nail Cortisol Collection

Fingernail clippings from all ten fingernails are collected to measure nail cortisol levels.

Andere namen:
  • Fingernail Collection; Nail Sample Collection
Diagnostische toets: WatchPAT Sleep Assessment

FDA-approved wearable sleep assessment device used to measure sleep/wake times and sleep quality during the saliva collection period.

Andere namen:
  • WatchPAT 300; WatchPAT ONE; Wearable Sleep Monitor
Gedragsmatig: Morning and Evening Diaries

Participants complete brief morning and evening diaries to record sleep, caffeine intake, medication use, symptoms, stress, affect, daily events, and other factors that may influence cortisol measurements.

Ander: MEMS Cap Adherence Monitoring

Electronic caps used with saliva collection tubes to record date and time of each bottle opening, providing objective assessment of saliva collection adherence.

Andere namen:
  • Aardex MEMS Caps; Medication Event Monitoring System Caps
Ander: OnTimePoint Application

Mobile/web-based application that provides saliva collection reminders and records sample collection timing and participant-reported wake times.

Ander: Survey and Questionnaire Assessment

Collection of demographic, psychosocial, sleep, medication, socioeconomic, acceptability, and health-related survey data from survivors, siblings, and caregivers.
Siblings of ALL Survivors

Biological or household siblings of enrolled ALL survivors, aged 8-18 years.
Diagnostische toets: Salivary Cortisol Collection

Participants collect five saliva samples per day on three days within a 14-day period (wake, +30 min, +45 min, +60 min, bedtime) to assess diurnal cortisol rhythm and cortisol awakening response.

Andere namen:
  • Saliva Sampling; Saliva Collection
Diagnostische toets: Blood Biomarker Collection

Collection of blood samples to measure high-sensitivity C-reactive protein, pro-inflammatory cytokines, dehydroepiandrosterone, and luteinizing hormone. Hybrid participants undergo venipuncture (~3 mL blood). Remote participants use the FDA-approved RedDrop One capillary blood collection device.

Andere namen:
  • Blood Collection; Blood Sampling; Venipuncture; RedDrop One Blood Collection
Diagnostische toets: Hair Cortisol Collection

Collection of a small hair sample from the posterior vertex of the scalp to measure long-term cortisol exposure. Hair is cut close to the scalp and stored for laboratory analysis.

Andere namen:
  • Hair Sample Collection
Diagnostische toets: Nail Cortisol Collection

Fingernail clippings from all ten fingernails are collected to measure nail cortisol levels.

Andere namen:
  • Fingernail Collection; Nail Sample Collection
Diagnostische toets: WatchPAT Sleep Assessment

FDA-approved wearable sleep assessment device used to measure sleep/wake times and sleep quality during the saliva collection period.

Andere namen:
  • WatchPAT 300; WatchPAT ONE; Wearable Sleep Monitor
Gedragsmatig: Morning and Evening Diaries

Participants complete brief morning and evening diaries to record sleep, caffeine intake, medication use, symptoms, stress, affect, daily events, and other factors that may influence cortisol measurements.

Ander: MEMS Cap Adherence Monitoring

Electronic caps used with saliva collection tubes to record date and time of each bottle opening, providing objective assessment of saliva collection adherence.

Andere namen:
  • Aardex MEMS Caps; Medication Event Monitoring System Caps
Ander: OnTimePoint Application

Mobile/web-based application that provides saliva collection reminders and records sample collection timing and participant-reported wake times.

Ander: Survey and Questionnaire Assessment

Collection of demographic, psychosocial, sleep, medication, socioeconomic, acceptability, and health-related survey data from survivors, siblings, and caregivers.
Caregivers

Primary caregivers residing full-time with enrolled survivors and siblings.
Ander: Survey and Questionnaire Assessment

Collection of demographic, psychosocial, sleep, medication, socioeconomic, acceptability, and health-related survey data from survivors, siblings, and caregivers.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Enrollment Feasibility
Tijdsspanne: Baseline through study completion, approximately 3 months after enrollment

Proportion of participants approached that enroll in the study
Baseline through study completion, approximately 3 months after enrollment
Saliva Sampling Feasibility
Tijdsspanne: Baseline through study completion, approximately 3 months after enrollment

Proportion of participants who complete the saliva sampling procedures will adhere to the timing of the saliva sampling
Baseline through study completion, approximately 3 months after enrollment
Blood Sampling Feasibility
Tijdsspanne: Baseline through study completion, approximately 3 months after enrollment

Proportion of participants enrolled who complete the blood sample collection
Baseline through study completion, approximately 3 months after enrollment
Hair Sampling Feasibility
Tijdsspanne: Baseline through study completion, approximately 3 months after enrollment

Proportion of participants enrolled that completed the hair sample collection
Baseline through study completion, approximately 3 months after enrollment
Fingernail Sampling Feasibility
Tijdsspanne: Baseline through study completion, approximately 3 months after enrollment

Proportion of participants enrolled that completed the fingernail sample collection
Baseline through study completion, approximately 3 months after enrollment
Overall Study Procedure Feasibility
Tijdsspanne: Baseline through study completion, approximately 3 months after enrollment

Proportion of participants enrolled that completed each study procedure
Baseline through study completion, approximately 3 months after enrollment

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Saliva Sampling Acceptability-Acceptability Measure
Tijdsspanne: Post study, approximately 3 months after enrollment

A measure of saliva sampling acceptability. Scores of ≥4 on a 5-point Likert scale will be indicative of intervention acceptability.
Post study, approximately 3 months after enrollment
Blood Sampling Acceptability-Acceptability Measure
Tijdsspanne: Post study, approximately 3 months after enrollment

A measure of blood sampling acceptability. Scores of ≥4 on a 5-point Likert scale will be indicative of intervention acceptability.
Post study, approximately 3 months after enrollment
Hair Sampling Acceptability-Acceptability Measure
Tijdsspanne: Post study, approximately 3 months after enrollment

A measure of hair sampling acceptability. Scores of ≥4 on a 5-point Likert scale will be indicative of intervention acceptability.
Post study, approximately 3 months after enrollment
Fingernail Sampling Acceptability-Acceptability Measure
Tijdsspanne: Post study, approximately 3 months after enrollment

A measure of fingernail sampling acceptability. Scores of ≥4 on a 5-point Likert scale will be indicative of intervention acceptability.
Post study, approximately 3 months after enrollment
Overall Biospecimen Acceptability-Acceptability Measure
Tijdsspanne: Post study, approximately 3 months after enrollment

A measure of overall biospecimen acceptability. Scores of ≥4 on a 5-point Likert scale will be indicative of intervention acceptability.
Post study, approximately 3 months after enrollment
Overall Study Procedure Acceptability-Acceptability Measure
Tijdsspanne: Post study, approximately 3 months after enrollment

A measure of overall study acceptability. Scores of ≥4 on a 5-point Likert scale will be indicative of overall study acceptability.
Post study, approximately 3 months after enrollment
Neighborhood Socioeconomic Status (nSES)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with cortisol awakening response. Cortisol awakening response will be measured via the slope of four morning saliva samples (upon waking, +30 minutes, +45 minutes, +60 minutes) across three days, with values at each time point averaged across days.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Cortisol Diurnal Rhythm
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with cortisol diurnal rhythm. Cortisol diurnal rhythm will be measured via the slope of five daily saliva samples (upon waking, +30 minutes, +45 minutes, +60 minutes, bedtime) across three days, with values at each time point averaged across days.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Hair Cortisol Concentration
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with hair cortisol concentration. Hair cortisol concentration will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Nail Cortisol Concentration
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with nail cortisol concentration. Nail cortisol concentration will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and High-Sensitivity C-Reactive Protein (hs-CRP)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with high-sensitivity c-reactive protein (hs-CRP). Plasma hs-CRP will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interferon gamma (IFN-y)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interferon gamma (IFN-y). Plasma IFN-y will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interleukin 1 beta (IL-1β)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interleukin 1 beta (IL-1β). Plasma IL-1β will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interleukin 2 (IL-2)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interleukin 2 (IL-2). Plasma IL-2 will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interleukin 4 (IL-4)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interleukin 4 (IL-4). Plasma IL-4 will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interleukin 6 (IL-6)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interleukin 6 (IL-6). Plasma IL-6 will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interleukin 10 (IL-10)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interleukin 10 (IL-10). Plasma IL-10 will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interleukin 12 (IL-12p70)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interleukin 12 (IL-12p70). Plasma IL-12p70 will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Interleukin 17A (IL-17A)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with interleukin 17A (IL-17A). Plasma IL-17A will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends
Neighborhood Socioeconomic Status (nSES) and Tumor Necrosis Factor - alpha (TNF- α)
Tijdsspanne: Post study, approximately 6 months after accrual ends

Determine whether neighborhood socioeconomic status (nSES), operationalizing using participants' address histories to estimate long-term neighborhood conditions, is associated with Tumor Necrosis Factor - alpha (TNF- α). Plasma (TNF- α) will be evaluated as a continuous measure.
Post study, approximately 6 months after accrual ends

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

St. Jude Children's Research Hospital

Medewerkers

National Cancer Institute (NCI)

Onderzoekers

  • Hoofdonderzoeker: Bria Gresham, PhD, St. Jude Children's Research Hospital

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 april 2028

Studie voltooiing (Geschat)

1 oktober 2029

Studieregistratiedata

Eerst ingediend

25 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

13 oktober 2026

Eerst geplaatst (Werkelijk)

20 oktober 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • FARSC
  • U54CA302464 (Subsidie/contract van de Amerikaanse NIH)
  • NCI-2026-06979 (Andere identificatie: NCI Clinical Trial Registration Program)

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren